• Active Substance: Brolucizumab
  • Name: Beovu®
  • Therapeutic area: Neovascular age-related macular degeneration
  • Pharmaceutical company: Novartis Pharma GmbH


Time table:

  • Publication of project plan: 18.12.2019
  • Publication of final assessment: 12.03.2020


Assessment information:

G-BA assessment available

  • Title: Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)
  • Author/Co-Author: FIMEA (Finland), AEMPS/ AETSA (Spain)
  • Dedicated Reviewers: HAS (France), AOTMiT (Poland), HVB (Austria), RER (Italy)
  • Observer: HTA department/EC Ukraine